Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

381710

registered interest
date	17/06/2015
answering body	Ministry of Defence
answering dept id	11
answering dept short name	Defence
answering dept sort name	Defence
hansard heading	Armed Forces: Mefloquine
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government how many (1) serving and (2) former service men and women have required psychiatric treatment after taking Lariam (mefloquine).
tabling member printed	Baroness Corston
uin	HL563
answer	answer is ministerial correction date of answer 25/06/2015 answer text <p>Between 1 April 2007 and 31 December 2014, 16,473 UK Regular Armed Forces personnel were prescribed mefloquine (commercial name Lariam). Up to 31 March 2015, 1,066 (6 per cent) were assessed as having a mental health disorder at their initial assessment at an MOD Department for Community Mental Health (DCMH) or on admission to an MOD in-patient provider. It is not possible from centrally-held data to identify whether an assessment is associated with a patient having taken mefloquine.</p><p> </p><p>Former Service men and women are treated by the NHS and their status as a veteran is not always recorded on their NHS medical records. It is therefore not possible to say how many former Service personnel have required psychiatric treatment after taking mefloquine.</p><p> </p><p>Between 1 April 2007 and 31 December 2014, 536 UK Armed Forces personnel were prescribed mefloquine prior to or whilst on deployment to Afghanistan. Up to 31 March 2015, 43 (8 per cent) were assessed as having a mental health disorder at their initial assessment at an MOD DCMH or on admission to an MOD in-patient provider.</p><p> </p><p> </p><p> </p> answering member printed Earl Howe grouped question UIN HL564 question first answered 25/06/2015 15:20:29 answering member 2000 label Biography information for Earl Howe
tabling member	215 label Biography information for Baroness Corston

381711

registered interest
date	17/06/2015
answering body	Ministry of Defence
answering dept id	11
answering dept short name	Defence
answering dept sort name	Defence
hansard heading	Armed Forces: Mefloquine
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government how many service men and women who were deployed to Afghanistan between 2007 and 2014, and were required to take Lariam (mefloquine), subsequently required mental health treatment.
tabling member printed	Baroness Corston
uin	HL564
answer	answer is ministerial correction date of answer 25/06/2015 answer text <p>Between 1 April 2007 and 31 December 2014, 16,473 UK Regular Armed Forces personnel were prescribed mefloquine (commercial name Lariam). Up to 31 March 2015, 1,066 (6 per cent) were assessed as having a mental health disorder at their initial assessment at an MOD Department for Community Mental Health (DCMH) or on admission to an MOD in-patient provider. It is not possible from centrally-held data to identify whether an assessment is associated with a patient having taken mefloquine.</p><p> </p><p>Former Service men and women are treated by the NHS and their status as a veteran is not always recorded on their NHS medical records. It is therefore not possible to say how many former Service personnel have required psychiatric treatment after taking mefloquine.</p><p> </p><p>Between 1 April 2007 and 31 December 2014, 536 UK Armed Forces personnel were prescribed mefloquine prior to or whilst on deployment to Afghanistan. Up to 31 March 2015, 43 (8 per cent) were assessed as having a mental health disorder at their initial assessment at an MOD DCMH or on admission to an MOD in-patient provider.</p><p> </p><p> </p><p> </p> answering member printed Earl Howe grouped question UIN HL563 question first answered 25/06/2015 15:20:29 answering member 2000 label Biography information for Earl Howe
tabling member	215 label Biography information for Baroness Corston

381715

registered interest
date	17/06/2015
answering body	Ministry of Defence
answering dept id	11
answering dept short name	Defence
answering dept sort name	Defence
hansard heading	Mefloquine
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what stocks of Lariam (mefloquine) they currently hold.
tabling member printed	Baroness Corston
uin	HL568
answer	answer is ministerial correction date of answer 25/06/2015 answer text <p>As at 22 June 2015, the Ministry of Defence holds 11,505 packs of mefloquine (commercial name Lariam) each containing eight tablets.</p> answering member printed Earl Howe question first answered 25/06/2015 15:19:31 answering member 2000 label Biography information for Earl Howe
tabling member	215 label Biography information for Baroness Corston

156457

registered interest
date	18/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mefloquine
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what assessment the Medicines and Healthcare Products Regulatory Agency and the Advisory Committee for Malaria Prevention have made of the United States Food and Drug Administration's Safety Communication of 29 July 2013 warning of the risk of psychiatric and nerve side effects from taking Lariam (mefloquine) as a malaria prophylactic.
tabling member printed	Baroness Corston
uin	HL2899
answer	answer is ministerial correction date of answer 02/12/2014 answer text <p>Mefloquine (brand name Lariam) is one of several drugs licensed for the prevention (<strong>c</strong>hemoprophylaxis) or treatment of malaria. As with any medicine, mefloquine may cause side effects in some people and the potential risks should be balanced against the expected benefits of therapy. Information on possible side effects is available to the medical profession via the Summary of Product Characteristics (SmPC), and to patients via the Patient Information Leaflet.</p><p> </p><p> </p><p> </p><p>In 2013, the Medicines and Healthcare products Regulatory Agency (MHRA) strengthened the warnings in the mefloquine SmPC, particularly regarding the well-established risk of neuropsychiatric side effects. The licence holder (Roche) also issued a letter to healthcare professionals at the end of October 2013 to increase awareness of these possible risks, alongside a prescriber checklist and patient alert card to aid compliance with the warnings. In November 2013, the MHRA issued a further communication to healthcare professionals on the risks of mefloquine via its Drug Safety Update bulletin:</p><p> </p><p> </p><p> </p><p>www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON336723</p><p> </p><p> </p><p> </p><p>As with all medicines, the MHRA will keep the safety of mefloquine under continual review.</p><p> </p><p> </p><p> </p><p>The Advisory Committee for Malaria Prevention (ACMP) carefully considered all available data following the Food and Drug Administration’s safety communication and subsequent modification of the SmPC by Roche in September 2013. SmPC recommendations for monitoring of liver function and eye assessment in long term use have also been added to the guidelines. The ACMP continues to believe that mefloquine is a valuable option for prophylaxis against malaria when appropriate risk assessments are undertaken.</p><p> </p> answering member printed Earl Howe question first answered 02/12/2014 12:38:24 answering member 2000 label Biography information for Earl Howe
tabling member	215 label Biography information for Baroness Corston

156460

registered interest
date	18/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Malaria
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what the unit cost is of (1) Lariam (mefloquine), and (2) malarone.
tabling member printed	Baroness Corston
uin	HL2902
answer	answer is ministerial correction date of answer 02/12/2014 answer text <p>The current edition of the British National Formulary lists the price of Lariam (mefloquine) as £14.53 for a pack of 8 tablets and the price of Malarone (proguanil hydrochloride with atovaquone) as £25.21 for a pack of 12 tablets.</p><p> </p> answering member printed Earl Howe question first answered 02/12/2014 12:37:24 answering member 2000 label Biography information for Earl Howe
tabling member	215 label Biography information for Baroness Corston

156461

registered interest
date	18/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Malaria
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government on how many occasions the Advisory Committee for Malaria Prevention has met in the last two years.
tabling member printed	Baroness Corston
uin	HL2903
answer	answer is ministerial correction date of answer 02/12/2014 answer text <p>Full meetings of the Advisory Committee for Malaria Prevention occurred in March and August of 2012 and January and December of 2013. The next full meeting is planned for January 2015. There was a sub-group meeting in 2014 to approve the 2014 version of the <em>Guidelines for malaria prevention in travellers from the UK</em>.</p><p> </p> answering member printed Earl Howe question first answered 02/12/2014 12:41:24 answering member 2000 label Biography information for Earl Howe
tabling member	215 label Biography information for Baroness Corston

76626

registered interest
date	09/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Meningitis
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what is the timetable for the procurement and introduction of the meningitis B vaccine.
tabling member printed	Baroness Corston
uin	HL968
answer	answer is ministerial correction date of answer 23/07/2014 answer text <p>We are committed to introducing this vaccine as soon as practicable, in line with the Joint Committee on Vaccination and Immunisation’s recommendation, subject to the manufacturer offering the vaccine at a cost-effective price.</p> answering member printed Earl Howe question first answered 23/07/2014 12:36:57 answering member 2000 label Biography information for Earl Howe
tabling member	215 label Biography information for Baroness Corston